Inicio › Cáncer de riñón (carcinoma de células renales) › Minnesota › Rochester
Ensayos clínicos de Cáncer de riñón (carcinoma de células renales) en Rochester, MN
14 estudios para Cáncer de riñón (carcinoma de células renales) buscan participantes en centros de Rochester y alrededores (a unos 30 millas). Abra un estudio para ver quién puede participar y cómo contactar con el equipo.
Texto oficial del estudio (inglés)
A Phase 1 Study of the Safety and Tolerability of CTX-10726
ReclutandoFase 1
- Mayo Clinic Rochester, Rochester
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
ReclutandoFase 1
- Exelixis Clinical Site #68, Rochester
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
ReclutandoFase 2
- Mayo Clinic in Rochester, Rochester
Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
ReclutandoEstudio observacional
- Mayo Clinic Rochester, Rochester
Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial
ReclutandoFase 2
- Mayo Clinic in Rochester, Rochester
Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer
ReclutandoFase 1/2
- Mayo Clinic Hospital, Methodist Campus, Research Pharmacy, Rochester
- Mayo Clinic Cancer Center Outpatient Pharmacy, Rochester
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
ReclutandoEstudio observacional
- Mayo Clinic (Rochester), Rochester
Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma
ReclutandoFase 1
- Xencor Investigative Site, Rochester
A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors
ReclutandoFase 1/2
- Mayo Clinic, Rochester
KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors
ReclutandoFase 1
- Mayo Clinic Comprehensive Cancer Center, Rochester
VSV-IFNβ-NIS With Ipilimumab and Nivolumab for the Treatment of Advanced or Metastatic Clear Cell Renal Cell Carcinoma
ReclutandoFase 2
- Mayo Clinic in Rochester, Rochester
Immune Checkpoint Inhibitor Response in Solid Tumors Using a Live Tumor Diagnostic Platform
ReclutandoEstudio observacional
- Mayo Clinic in Rochester, Rochester
A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression
ReclutandoFase 1/2
- Mayo Clinic, Rochester
A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)
ReclutandoFase 1/2
- Mayo Clinic in Minnesota, Rochester
Ensayos de Cáncer de riñón (carcinoma de células renales) en otras ciudades
- Houston, TX35 estudios
- New York City, NY27 estudios
- Dallas, TX23 estudios
- Nashville, TN23 estudios
- St. Louis, MO23 estudios
- Los Angeles, CA20 estudios
- Boston, MA16 estudios
- Baldwin Park, CA16 estudios
- Pittsburgh, PA15 estudios
- Philadelphia, PA15 estudios
- Queens, NY15 estudios
- Cleveland, OH14 estudios
Otros estudios en Rochester
- Cáncer de seno42 estudios
- Cáncer de pulmón de células no pequeñas37 estudios
- Cáncer metastásico31 estudios
- Cáncer (todos los tipos)30 estudios
- Cáncer de ovario29 estudios
- Cáncer del colon y del recto29 estudios
- Mieloma múltiple24 estudios
- Fallo cardíaco22 estudios
- Cáncer de próstata22 estudios
- Cáncer de páncreas22 estudios
- Cáncer de endometrio20 estudios
- Cáncer de pulmón20 estudios
De ClinicalTrials.gov, datos obtenidos el 6 oct 2026. Cada estudio establece sus propios criterios de elegibilidad; el equipo del estudio decide quién puede participar.